Navigation Links
Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium
Date:5/6/2011

LOS ANGELES, May 6, 2011 /PRNewswire/ -- Last week in Alexandria, VA, the Department of Health and Human Services (HHS) Office of Grants and Acquisition Policy and Accountability (OGAPA) recognized the National Institutes of Health's Commercialization Assistance Program (and its Niche Assessment Program) for a special "team" recognition award for superior efforts to assist over 600 companies in bringing their applications to market and "contributing to public health." The award was made at the 2011 Acquisition, Grants, and Small Business Symposium. CEO Rohit Shukla was present and recognized as part of the team. The two-day symposium also highlighted various aspects of the acquisition, grants, and small business planning process to enrich stakeholder and customer knowledge.

The Larta-managed National Institutes of Health Commercialization Assistance Program (NIH-CAP) has assisted more than 600 NIH-funded SBIR Phase II businesses identify and accomplish their commercialization goals. The NIH-CAP is a 10-month mentoring and partnering-oriented effort geared to accelerate the commercial and market readiness of award-winning life science companies supported by NIH institutes across a variety of health care areas. Since 2004, Larta has assisted 105 NIH-CAP companies raise over $410 million in capital, and has had 12 acquisitions (10 companies and 2 technologies) result from the program. As part of this effort, Larta Institute has developed a compelling innovation "eco system" with industry, domain and functional experts focused on helping to advance these innovative products and services.

One of the many successful past participants in Larta's NIH-CAP is Colorado engineering company, Quest Product Development Corp. Quest participated in the 2008-09 NIH-CAP program cycle, working to continue research into their novel CardioQuest™ Cardiac Synchronization Technology.

CEO of Quest, James Houston, found great benefit from NIH-CAP participation, stating, "NIH-CAP helped us focus on our technology and path to commercialization, as well as pointed out concerns we needed to address and market opportunities we might look at. The work around preparing the road show and strategic action plan, the practice presentations and the panel feedback were extremely valuable."

Larta's commercialization programs are designed to support early stage entrepreneurs and drive entrepreneurship across the nation. In addition to NIH, Larta also partners with the National Science Foundation (NSF), U.S. Department of Agriculture (USDA) and Department of Energy (DOE).

About Larta Institute

Larta is a professional services firm that helps turn government-funded innovations into enterprises. Our clients range from federal agencies in the U.S. to governments and regional authorities across the globe. We increase the market and investor readiness of emerging entrepreneurs supported by these institutions. Larta has over 17 years of experience designing and managing customized mentoring programs to help innovators reach commercial markets. We credit our proven track record of success to our unrivaled expertise and extensive global network of subject-matter experts, seasoned entrepreneurs, investors, and Fortune 1000 companies. Since 1993, we have assisted hundreds of entrepreneurs to raise over $1.5 billion in capital.

Media Contact:
Rebecca Lauber
Programs and Business Development Associate
rlauber@larta.org
213.538.1445
http://www.larta.org/

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Larta Institute
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Larta Institute NIH Success Stories Featured in 2011 California Biomedical Industry Report
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
4. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
5. Cyntellect to Collaborate With the Burnham Institute for Medical Research
6. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
7. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
8. Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript
9. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
10. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
11. Annual List of Best Doctors in Dallas Showcases Texas Institute for Surgery Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... data bioInformatics portal. In response to client demand KbioBox developed a sophisticated “3 ... biodesign program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ ...
(Date:12/8/2016)... ... December 08, 2016 , ... This CAST literature review and ... crops. The authors focus on the economic effects in countries that are major global ... biotech crops and the resultant risk of low level presence (LLP) puts large volumes ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... 2016  Partnering to fuel Philadelphia,s ... of Southeastern Pennsylvania (" Ben ... of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... a $6 million funding initiative over a four year ... Responding to a burgeoning economic vitality in digital health, ...
Breaking Biology Technology:
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported a ... over 40 granted and pending patents. ... , The Company,s IP portfolio expansion ... Device, and Method Estimating Force Applied to a Touch Surface, " ... components needed to estimate the force and pressure applied to touch surfaces ...
(Date:12/6/2016)... 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... offering of €500.0 million principal amount of its 1.414% senior ... its 2.425% senior unsecured notes due 2026. ... December 13, 2016, subject to the satisfaction of customary closing conditions.  ... The Company intends to use the ...
(Date:12/5/2016)... 5, 2016  The Office of Justice Programs, ... CT Scans Enhance or Replace Medico Legal Autopsies?" ... supporting or replacing forensic autopsies with postmortem X-ray ... In response to recommendations made by The ... CT scans as a potential component of medicolegal ...
Breaking Biology News(10 mins):